Reimmunization with 23-Valent Pneumococcal Vaccine for Patients Infected with Human Immunodeficiency Virus Type 1: Clinical, Immunologic, and Virologic Responses

Abstract
We determined the immunogenicity and safety of reimmunization with the 23-valent polysaccharide pneumococcal vaccine in patients infected with human

This publication has 50 references indexed in Scilit: